BioSpace News Archive

Seventeen subjects with advanced cancer pain received epidural RTX (0.4 to 25 mcg). No dose limiting toxicities were reported. A majority of patients reported meaningful pain reduction of 30% or more from baseline. Sorrento expects to submit to the FDA a request to proceed with a Phase 3 clinical trial in this orphan indication imminently. SAN DIEGO, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced the public release of the results of it

While studying the genetics of the androgen receptor, a team of scientists discovered a possible breakthrough treatment for COVID-19. The team led by Andy Goren, MD from Applied Biology, Flavio A. Cadegiani, MD, MSc, PhD from Corpometria Institute in Brazil, along with other collaborators, have published their discovery in several medical journ

Funds Support Further Development of V-Wave Implantable Interatrial Cardiac Shunt for Heart Failure and Pulmonary Hypertension

Wave Life Sciences Ltd., a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced that it has commenced an underwritten public offering of its ordinary shares.

The Centers for Medicare & Medicaid Services released a memorandum on Thursday, September 17 that requires Nursing Homes to permit access to health care workers who are not employees of the facility if they meet certain screening requirements.

Micro-Tech Endoscopy recently launched the Napoleon Endoscopic Measuring Device.

MEDISCA, a global leader in the personalized pharmaceutical industry, has announced that the revolutionary compounding technology, repurposed and optimized over a seven-year period, is available exclusively from MEDISCA, and, therefore, MEDISCA is actively taking steps to inform its competitors about MEDISCA’s expanding patent portfolio relating to its MAZ mixers.

“The ADME-Tox testing space continues to evolve at an impressive rate, and we see incredibly exciting advancements as drug developers strive for greater efficiency and early predictivity of success.

Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, announced that it has determined not to proceed with its proposed public offering of 4,500,000 shares of its common stock previously announced on September 21, 2020.

NeuroTherapia, Inc., a clinical-stage company focused on developing therapies for neurodegenerative diseases, announced today the closing of its Series A financing of $8.8M . The Series A round, led b